Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
40.4M
-
Shares change
-
-6.49M
-
Total reported value, excl. options
-
$48M
-
Value change
-
-$16.2M
-
Put/Call ratio
-
0.47
-
Number of buys
-
37
-
Number of sells
-
-37
-
Price
-
$1.19
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q1 2022
96 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q1 2022.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.4M shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (6.26M shares), FMR LLC (5.53M shares), Artal Group S.A. (3.5M shares), Ally Bridge Group (NY) LLC (3.36M shares), Flagship Pioneering Inc. (2.94M shares), Omega Fund Management, LLC (2.51M shares), VANGUARD GROUP INC (2.26M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.9M shares), Samsara BioCapital, LLC (1.9M shares), and STATE STREET CORP (1.14M shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.